IP Library › Granted Patent US 12,404,281
Granted Patent B2
US 12,404,281 · App. 18/227,561 · Granted Sep 2, 2025

Diaryl macrocycles as modulators of protein kinases

Inventors: Jingrong Jean Cui (Princeton, NJ); Yishan Li (Princeton, NJ); Evan W. Rogers (Princeton, NJ); Dayong Zhai (Princeton, NJ)
Assignee: TURNING POINT THERAPEUTICS, INC.
C07D498/18C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,281
App. No.
18/227,561
Granted
Sep 2, 2025
Kind
B2
Abstract

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

Claims (10)

1. A compound having structure:

2. A compound having structure:

or a salt thereof.

3. The compound of claim 2 that is

4. A compound having structure:

or a salt thereof.

5. The compound of claim 4 that is

6. A compound having structure:

or a salt thereof.

7. The compound of claim 6 that is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2025
From: CUI, JINGRONG JEAN; LI, YISHAN; ROGERS, EVAN W.; ZHAI, DAYONG
To: TP THERAPEUTICS, INC.
Reel/Frame 071251/0777 →
CHANGE OF NAME Recorded May 29, 2025
From: TP THERAPEUTICS, INC.
To: TURNING POINT THERAPEUTICS, INC.
Reel/Frame 071461/0047 →
Continuity (9)
Continuation 17485942 · Sep 27, 2021
Continuation 16797866 · Feb 21, 2020
Continuation 16204566 · Nov 29, 2018
Continuation 15609962 · May 31, 2017
Continuation 15113583
Provisional Application 62106301 · Jan 22, 2015
Provisional Application 62049326 · Sep 11, 2014
Provisional Application 61931506 · Jan 24, 2014
Related Publication 20240140964A1 · May 2, 2024
References Cited (202)
US 4838925A · Tseng · 1989 [cited by applicant]
US 4847382A · Hallenbach · 1989 [cited by applicant]
US 5639778A · Andersson · 1997 [cited by applicant]
US 5698578A · Heath et al. · 1997 [cited by applicant]
US 8497270B2 · Thuring et al. · 2013 [cited by applicant]
US 8680111B2 · Bailey · 2014 [cited by applicant]
US 8815872B2 · Yu · 2014 [cited by applicant]
US 8933084B2 · Andrews · 2015 [cited by applicant]
US 9090630B2 · Blom et al. · 2015 [cited by applicant]
US 9714258B2 · Cui · 2017 [cited by applicant]
US 10246466B2 · Cui et al. · 2019 [cited by applicant]
US 10294242B2 · Cui et al. · 2019 [cited by applicant]
US 10316044B2 · Cui et al. · 2019 [cited by applicant]
US 10618912B2 · Cui et al. · 2020 [cited by applicant]
US 20110029480A1 · Delucia · 2011 [cited by applicant]
US 20110294801A1 · Yu · 2011 [cited by applicant]
US 20120136859A1 · Shamsi et al. · 2012 [cited by applicant]
US 20130143895A1 · McAllister et al. · 2013 [cited by applicant]
US 20130203776A1 · Andrews · 2013 [cited by applicant]
US 20130245021A1 · Bi · 2013 [cited by applicant]
US 20130252961A1 · Bailey · 2013 [cited by applicant]
US 20140107099A1 · Blaney · 2014 [cited by applicant]
US 20140206605A1 · Beutner · 2014 [cited by applicant]
US 20160159808A1 · Kawasaki · 2016 [cited by applicant]
US 20160339027A1 · Carter · 2016 [cited by applicant]
US 20170002023A1 · Cui et al. · 2017 [cited by applicant]
US 20170334929A1 · Cui · 2017 [cited by applicant]
US 20180186813A1 · Cui · 2018 [cited by applicant]
US 20180194777A1 · Cui · 2018 [cited by applicant]
US 20180325901A1 · Cui · 2018 [cited by applicant]
US 20190169207A1 · Cui et al. · 2019 [cited by applicant]
US 20200216465A1 · Cui et al. · 2020 [cited by applicant]
CL 2012003227 · 2013 [cited by applicant]
CN 102143750 · 2011 [cited by applicant]
CN 102971322 · 2013 [cited by applicant]
JP 2012502043 · 2012 [cited by applicant]
JP 2017503867A · 2017 [cited by applicant]
WO 1997035550 · 1997 [cited by applicant]
WO 2000071118 · 2000 [cited by applicant]
WO 2002010169 · 2002 [cited by applicant]
WO 0246197A1 · 2002 [cited by applicant]
WO 2002076925 · 2002 [cited by applicant]
WO 2004052315 · 2004 [cited by applicant]
WO 2010028116 · 2010 [cited by applicant]
WO 2010033941 · 2010 [cited by applicant]
WO 2010048314 · 2010 [cited by applicant]
WO 2010051549 · 2010 [cited by applicant]
WO 2010063487 · 2010 [cited by applicant]
WO 2010086040 · 2010 [cited by applicant]
WO 2011006074 · 2011 [cited by applicant]
WO 2011071716 · 2011 [cited by applicant]
WO 2011071725 · 2011 [cited by applicant]
WO 2011146336 · 2011 [cited by applicant]
WO 2012034091 · 2012 [cited by applicant]
WO 2012034095 · 2012 [cited by applicant]
WO 2012075393 · 2012 [cited by applicant]
WO 2012136859 · 2012 [cited by applicant]
WO 2013001310 · 2013 [cited by applicant]
WO 2013028465 · 2013 [cited by applicant]
WO 2013045653 · 2013 [cited by applicant]
WO 2013045656A1 · 2013 [cited by applicant]
WO 2013045701 · 2013 [cited by applicant]
WO 2013045702 · 2013 [cited by applicant]
WO 2013059587 · 2013 [cited by applicant]
WO 20130143895 · 2013 [cited by applicant]
WO 2013132376 · 2013 [cited by applicant]
WO 2013134219 · 2013 [cited by applicant]
WO 2013134228 · 2013 [cited by applicant]
WO 2013147711 · 2013 [cited by applicant]
WO 2014118186 · 2014 [cited by applicant]
WO 2014173928 · 2014 [cited by applicant]
WO 2015073267 · 2015 [cited by applicant]
WO 2015112806 · 2015 [cited by applicant]
WO 2016070241 · 2016 [cited by applicant]
WO 2016097869 · 2016 [cited by applicant]
WO 2016133838 · 2016 [cited by applicant]
WO 2016144844 · 2016 [cited by applicant]
WO 2016144846 · 2016 [cited by applicant]
WO 2016177658 · 2016 [cited by applicant]
WO 2017004342 · 2017 [cited by applicant]
WO 2017007759 · 2017 [cited by applicant]
WO 2017015367 · 2017 [cited by applicant]
WO 20170002023 · 2017 [cited by applicant]
WO 2017075107 · 2017 [cited by applicant]
WO 2017152076 · 2017 [cited by applicant]
WO 2018022911 · 2018 [cited by applicant]
WO 2018112027 · 2018 [cited by applicant]
WO 2018140554 · 2018 [cited by applicant]
WO 2019023417 · 2019 [cited by applicant]
Miller et al., “Solvent Systems for Crystallization and Polymorph Selection” Chapter 3 in Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics Series Biotechnology: Pharmaceutical Aspects vol. VI Au… [cited by applicant]
International Search Report and Written Opinion prepared for PCT/US2015/012597, mailed Aug. 28, 2015, 11 pages. [cited by applicant]
International Search Report and Written Opinion prepared for PCT/US2016/040329, mailed Sep. 7, 2016, 13 pages. [cited by applicant]
International Search Report and Written Opinion prepared for PCT/US2016/040972, mailed Sep. 13, 2016, 8 pages. [cited by applicant]
European Search Report issued in EP 16828471, completed Mar. 15, 2019. [cited by applicant]
European Search Report issued in EP 16818768, completed Jan. 22, 2019. [cited by applicant]
Wang et al., “Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design,” Bioorganic & Medicinal Chemistry Letters (2013), 23(11), 3149-3153. [cited by applicant]
Gavrin et al., “Synthesis of Pyrazolo[1,5-alpha]pyrimidinone Regioisomers,” Journal of Organic Chemistry (2007), 72(3), 1043-1046. [cited by applicant]
Roever et al., “Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists,” Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3604-3608. [cited by applicant]
Golubovskaya VM, Front Biosci (Landmark Ed). 2014; 19: 687-706. [cited by applicant]
Jordan, “Tamoxifen: A Most Unlikely Pioneering Medicine”, Nature Reviews, vol. 2, Mar. 2003, pp. 205-213. [cited by applicant]
Hackam et al., “Translation of Research evidence From Animals to Humans”, JAMA, 2006; 296(14): 1731-1732. [cited by applicant]
Sequist, L.V., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TK1 therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19, 2240-2247. [cited by applicant]
Zhang, Z. et al., Nat. Genet. 2012, 44, 852-860. [cited by applicant]
Cui, J. J. et al., J. Med. Chem. 2011, 54, 6342-6363. [cited by applicant]
Katayama, R. et al., Sci. Transl. Med. 2012, 4, 120ra17. [cited by applicant]
Quintas-Cardama, A. et al., Nat. Rev. Drug Discov. 2011, 10(2), 127-40. [cited by applicant]
Pesu, M. et al., Immunol. Rev. 2008, 223, 132-142. [cited by applicant]
Murray, P.J., J. Immunol. 2007, 178(5), 2623-2329. [cited by applicant]
Muller, M. et al., Nature 1993, 366(6451), 129-135. [cited by applicant]
Neubauer, H. et al., Cell 1998 93(3), 397-409. [cited by applicant]
Nosaka, T. et al., Science 1995, 270(5237), 800-802. [cited by applicant]
Vainchenker, W. et al., Semin. Cell. Dev. Biol. 2008, 19(4), 385-393. [cited by applicant]
Levine, R.L. etal., Cancer Cell 2005, 7(4), 387-397. [cited by applicant]
Kralovics, R. et al., N. Engl. J. Med. 2005, 253(17), 1779-1790. [cited by applicant]
James, C. et al., Nature 2005, 434(7037), 1144-1148. [cited by applicant]
Baxter, E.J. et al. Lancet 2005, 365(9464), 1054-1061. [cited by applicant]
LaFave, L.M. et al., Trends Pharmacol. Sci. 2012, 33(11), 574-582. [cited by applicant]
Verstovsek, S. et al., N. Engl. J. Med. 2012, 366(9), 799-807. [cited by applicant]
Quintas-Cardama, A. et al., Blood 2010, 115(15), 3109-3117. [cited by applicant]
Nefedova, Y. et al., Cancer Res 2005; 65(20): 9525-35. [cited by applicant]
Davies, K. D. et al., Clin Cancer Res 2013, 19 (15): 4040-4045. [cited by applicant]
Awad, M. M. et al., N Engl J Med. 2013, 368(25):2396-2401. [cited by applicant]
Charest A, et al Genes Chromosomes Cancer 2003, 37, 58. [cited by applicant]
Takeuchi K, et al Nat. Med. 2012, 18, 378. [cited by applicant]
Gu TL, et al PLOS One. 2011, 6, el5640. [cited by applicant]
Lacronique V, et al. Science 1997, 278, 5341, 1309-12. [cited by applicant]
Zhang S, et al Trends Pharmacol Sci. 2012, 33, 122. [cited by applicant]
Bromann PA, Oncogene 2004, 23, 7957-7968. [cited by applicant]
Summy JM, et al. Cancer Metastasis Rev. 2003, 22, 337-358. [cited by applicant]
Scancier F. et al. PLOS One. 2011, 6(2): el 7237. [cited by applicant]
Ongusaha PP, et al. EMBO J. 2003, 22, 1289-1301. [cited by applicant]
Hammerman PS, et al. Cancer Discov. 2011, 1, 78-89. [cited by applicant]
Tomasson MH, et al. Blood 2008, 111:4797-4808. [cited by applicant]
Yu J. et al., Cancer Cell, 2010, 17, 5, 443-54. [cited by applicant]
Advani, A.S. et al. Leukemia Research, 2002, 26, 8, 713-720. [cited by applicant]
Gottesman, M.M., Annu. Rev. Med., 2002, 53, 615-627. [cited by applicant]
Anastassiadis T, et al Nat Biotechnol. 2011, 29, 1039. [cited by applicant]
Vetrie D. et al. Nature 1993, 361, 226-233. [cited by applicant]
Mohamed AJ et al, immunological Reviews, 2009, 228, 58-73. [cited by applicant]
Grande, E. et al., Mol. Cancer Ther. 2011, 10, 569-579. [cited by applicant]
Monti, E. 2007. Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors in B. Teicher (Ed.), Cancer Drug Resistance (pp. 241-260). [cited by applicant]
McCarthy et al. “Tropomyosin receptor kinase inhibitors: a patent update 2009-2013,” Expert Opinions 2014, pp. 731-744. [cited by applicant]
Di Paolo JA, et al. Nature Chemical Biology 2011, 7, 41-50. [cited by applicant]
Park, M. et al., Cell 1986, 45, 895-904. [cited by applicant]
Trusolino, L. et al., Nature Rev. Mol. Cell Biol. 2010, 11, 834-848. [cited by applicant]
Sonbol, M.B. et al., Ther. Adv. Hematol. 2013, 4(1), 15-35. [cited by applicant]
Reiter A, et al. Cancer Res. 2005, 65, 7, 2662-7. [cited by applicant]
Sen, B., et al. Distinct interactions between SRC and MET in mediating resistance to SRC inhibition in head and neck cancer. Clin Cancer Res. 2010, 17, 1-11. [cited by applicant]
Xie, Q., et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in alioblastoma. Proc. Natl. Acad. Sci. U.S. A. 2012, 109, 570-575. [cited by applicant]
International Search Report and Written Opinion prepared for PCT/US2016/043132, mailed Sep. 28, 2016, 8 pages. [cited by applicant]
Liu L, et al. Nature, 2012, 483, 608-612. [cited by applicant]
Peterson et al., “Expanding the Scope of Crystal Form Evaluation in Parmaceutical Science” Journal of Pharmacy & Pharmaceutical Science 2006 9(3):317-326. [cited by applicant]
Gargallonis et al., “The molecular rationale of Src inhibition in colorectal carcinomas”, Int. J. Cancer: 134, 2019-2029 (2014). Published online Jun. 21, 2013. [cited by applicant]
Okamoto et al., “Identification of c-Src as a Potential Activation as a Cause of Resistance to c-Sro Published online Apr. 20, 2010 Inhibition”, Therapeutic Target for Gastric Cancer and of MET Mol Cancer Ther., May 201… [cited by applicant]
Vergani et al., “Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032”, Neoplasia. Dec. 2011; 13(12): 1132-42. [cited by applicant]
Pachter et al., “The Chemistry of Hortiamine and 6-Methoxyrhetsinine,” J. Am. Chem. Soc., 1961, 83, 635-642. [cited by applicant]
Kiselyov, Alexander S., “Solid support synthesis of 15-membered macrocycles containing a serotonin unit,” Tetrahedron Letters 46 (2005) 3007-3010. [cited by applicant]
Halland et al. “Small Macrocycles as Highly Active Integrin 0131 Antagonists,” ACS Medicinal Chemistry Letters, 2014, Jan. 10, 5, 193-198. [cited by applicant]
International Search Report and Written Opinion prepared for PCT/US2017/044214, mailed Dec. 1, 2017, 11 pages. [cited by applicant]
Couronne L, et al. Blood 2013, 122, 811. [cited by applicant]
Takahashi, M. et al. Cell. 1985, 42:581-588. [cited by applicant]
Schiller J H et al., N Engl J Med, 346: 92-98, 2002. [cited by applicant]
Pachnis, V., et al. Development 1993, 119, 1005-1017. [cited by applicant]
Schuchardt, A. et al. Nature 1994, 367:380-383. [cited by applicant]
Grieco, M. et al. Cell. 1990, 23; 60 (4):557-63. [cited by applicant]
Gainor JF, Shaw AT. Oncologist. 2013, 18(7):865-75. [cited by applicant]
Kentsis, A., et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Medd. 2012, 18, 1118-1122. [cited by applicant]
Yano, S., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68, 9479-9487. [cited by applicant]
Bardelli, A., et al. Amplification of the MIi'T Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discov. 2013, 3, 658-673. [cited by applicant]
Straussman, R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500-504. [cited by applicant]
Harbinski, F., et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012, 2, 948-959. [cited by applicant]
Parsons, S. J., et al. Src family kinases, key regulators of signal transduction. Oncogene, 2004, 23, 7906-7909. [cited by applicant]
Wojcik, E. J., et al. A novel activating function of SRC and STAT3 on HGF transcription in mammary carcinoma cells. Oncogene. 2006, 25, 2773-84. [cited by applicant]
Dulak AM et al. HGF-independent potentiation of EGFR action by MIi'I'. Oncogene. 2011, 30, 3625-3635. [cited by applicant]
Stabile, L. P., et al. c-SRC activation mediates erlotinib resistance in head and neck cancer by stimulating MET. Clin Cancer Res. 2012, 19, 1-13. [cited by applicant]
Bertotti, A., et al. Inhibition of SRC impairs the growth of MET-addicted gastric tumors. Clin Cancer Res. 2010, 16,3933-3943. [cited by applicant]
Wrobel CN, et al. Autocrine CSFIR activation promotes SRC-dependent disruption of mammary epithelial architecture. J Cell Biol. 2004, 165, 263-273. [cited by applicant]
Ravi V, et al. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011, 23, 361-366. [cited by applicant]
Bottaro, D. P. etal., Science 1991, 251, 802-804. [cited by applicant]
Gherardi, E. et al., Nature Rev. Cancer 2012, 12, 89-103. [cited by applicant]
Gridelli, C. et al., Cancer Treat Rev. 2014, 40, 300-306. [cited by applicant]
Liu Z, et al. J. Clin. Endocrinol. Metab. 2004, 89, 3503-3509. [cited by applicant]
Boccaccio, C.; Comoglio, P. M. Invasive growth: a MET-driven generic programme for cancer and stem cells. Nat. Rev. Cancer 2006, 6, 637-645. [cited by applicant]
Ma, PC et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008, 47, 1025-1037. [cited by applicant]
Maulik, G., et al. Role of the hepatocyte growth factor receptor, MET, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002, 13, 41-59. [cited by applicant]
Smolen, G. A., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U.S. A. 2006, 103, 2316-2321. [cited by applicant]
Ghiso, E.; Giordano, S. Targeting MET: why, where and how? Curr. Opin. Pharmacol. 2013, 13, 511-518. [cited by applicant]
Cooper, C. S., et al Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311, 29-33. [cited by applicant]
Otsuka, T., et al. MET autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998, 58, 5157-5167. [cited by applicant]
Sawyers, C., Nature 2004, 432, 294-297. [cited by applicant]
Engelman, J. A. et al., Science 2007, 316, 1039-1043. [cited by applicant]
Wilson, T.R. et al., Nature 2012, 487, 505-509. [cited by applicant]
Pulford, K. et al., Cell Mol. Life Sci. 2004, 61, 2939. [cited by applicant]
Manning, G. et al., Science 2002, 298, 1912-1934. [cited by applicant]
Morris, S.W. et al., Science 1994, 263, 1281. [cited by applicant]
Bischof, D. et al., Mol. Cell Biol., 1997, 17, 2312-2325. [cited by applicant]
Soda, M. et al., Nature 2007, 448, 561-566. [cited by applicant]
Mosse, Y. P. et al., Nature 2008, 455, 930-935. [cited by applicant]
Thiele, C. J. et al., Clin. Cancer Res. 2009, 15, 5962-5967. [cited by applicant]
Pierotti, M.A. et al., Cancer Lett. 2006, 232, 90-98. [cited by applicant]
Vaishnavi, A. et al., Nat. Med. 2013, 19, 1469-1472. [cited by applicant]
Verma, A. etal., Mol. Cancer Ther. 2011, 10, 1763-1773. [cited by applicant]